' 
SCIENTIFIC SCORE
Moderately Effective
Based on 8 Researches
8.1
USERS' SCORE
Good
Based on 2 Reviews
8.6
Supplement Facts
Serving Size: 2 Veg Capsules
Amount Per Serving
%DV
Alpha GPC (L-alpha-glycerylphosphorylcholine)
600 mg
*
Top Medical Research Studies
9
Alpha-GPC reduces Alzheimer's symptoms
Pharmacological enhancement of cholinergic neurotransmission alleviates neuroinflammation and improves functional outcomes in a triple transgenic mouse model of Alzheimer's disease.
High relevance to Alzheimer's treatment
We investigated the potential benefits of alpha-glyceryl-phosphoryl-choline (α-GPC) in tackling the complex challenges of Alzheimer's disease (AD). Using a triple transgenic mouse model known as 3xTg-AD, mice were treated with α-GPC for eight months starting at four months of age. This approach allowed us to assess its impact on both neuroinflammation and memory over a significant timeframe.
Our findings revealed that chronic treatment with α-GPC led to a notable reduction in amyloid deposits, which are often associated with AD. We observed improvements in the balance of the immune response within the brain, especially among important cells like astrocytes and microglia. These changes reflected not just a decrease in inflammation but also an increase in protective, anti-inflammatory molecules.
Furthermore, the treatment positively influenced synaptic function, crucial for memory and learning. Behaviorally, the α-GPC-treated mice demonstrated enhanced cognitive abilities, as evidenced by longer exploration times of new objects—a key indicator of memory function—compared to their untreated counterparts.
In summary, our research supports α-GPC as a promising candidate for therapeutic intervention in the early stages of Alzheimer's. Its ability to reduce inflammation and support brain health could provide new avenues for aiding memory and cognitive function as we age.
Our findings revealed that chronic treatment with α-GPC led to a notable reduction in amyloid deposits, which are often associated with AD. We observed improvements in the balance of the immune response within the brain, especially among important cells like astrocytes and microglia. These changes reflected not just a decrease in inflammation but also an increase in protective, anti-inflammatory molecules.
Furthermore, the treatment positively influenced synaptic function, crucial for memory and learning. Behaviorally, the α-GPC-treated mice demonstrated enhanced cognitive abilities, as evidenced by longer exploration times of new objects—a key indicator of memory function—compared to their untreated counterparts.
In summary, our research supports α-GPC as a promising candidate for therapeutic intervention in the early stages of Alzheimer's. Its ability to reduce inflammation and support brain health could provide new avenues for aiding memory and cognitive function as we age.
Read More
8
Alpha GPC shows promise for Alzheimer’s
Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type.
High relevance to Alzheimer's treatment.
A multicentre, randomised, controlled study examined how effective l-alpha-glyceryl-phosphorylcholine (alpha GPC) and ST200 (acetyl-l-carnitine) were for individuals with probable mild to moderate Alzheimer's disease. We involved 126 patients to see which treatment had a more positive effect on their cognitive abilities.
By using behavioural scales and psychometric tests, we carefully evaluated both approaches. Our findings highlighted that alpha GPC users experienced significant improvements across many neuropsychological measures. Although patients taking ST200 also showed some enhancements, the effects were not as pronounced.
Furthermore, we found that both treatments were well-tolerated, with minimal side effects reported by participants in either group. These promising results suggest that further investigation is needed. Larger, double-blind studies that combine clinical and biological assessments would help to confirm the benefits of alpha GPC over ST200 in treating Alzheimer's.
By using behavioural scales and psychometric tests, we carefully evaluated both approaches. Our findings highlighted that alpha GPC users experienced significant improvements across many neuropsychological measures. Although patients taking ST200 also showed some enhancements, the effects were not as pronounced.
Furthermore, we found that both treatments were well-tolerated, with minimal side effects reported by participants in either group. These promising results suggest that further investigation is needed. Larger, double-blind studies that combine clinical and biological assessments would help to confirm the benefits of alpha GPC over ST200 in treating Alzheimer's.
Read More
8
α-GPC improves memory in mice
Treatment with soybean lecithin-derived α-GPC (SHCog™) improves scopolamine-induced cognitive declines in mice via regulating cholinergic neurotransmission and enhancing neural plasticity in the hippocampus.
Study relevance is moderately low
We explored how α-GPC, derived from soybean lecithin and known as SHCog™, impacts cognitive decline in mice, particularly looking at memory issues related to scopolamine-induced impairment. The study involved the use of C57BL/6 J mice subjected to tests designed to evaluate their short-term and spatial memory.
Our key findings revealed that treatment with SHCog™ improved both short-term and spatial memory when compared to untreated mice experiencing cognitive decline. Notably, we observed that SHCog™ effectively reduced the levels of acetylcholinesterase (AChE), an enzyme elevated by scopolamine, while increasing choline acetyltransferase (ChAT), which was decreased by the same treatment.
Furthermore, SHCog™ influenced neural plasticity by restoring proteins, such as PSD-95 and brain-derived neurotrophic factor (BDNF), that were reduced due to scopolamine. Overall, our work suggests that incorporating SHCog™ into functional foods or supplements could potentially enhance memory and cognitive functions. However, it’s important to note that these findings, while promising, relate primarily to a mouse model of cognitive dysfunction rather than direct evidence of benefits for Alzheimer's disease in humans.
Our key findings revealed that treatment with SHCog™ improved both short-term and spatial memory when compared to untreated mice experiencing cognitive decline. Notably, we observed that SHCog™ effectively reduced the levels of acetylcholinesterase (AChE), an enzyme elevated by scopolamine, while increasing choline acetyltransferase (ChAT), which was decreased by the same treatment.
Furthermore, SHCog™ influenced neural plasticity by restoring proteins, such as PSD-95 and brain-derived neurotrophic factor (BDNF), that were reduced due to scopolamine. Overall, our work suggests that incorporating SHCog™ into functional foods or supplements could potentially enhance memory and cognitive functions. However, it’s important to note that these findings, while promising, relate primarily to a mouse model of cognitive dysfunction rather than direct evidence of benefits for Alzheimer's disease in humans.
Read More
Most Useful Reviews
8.8
Enhances memory clarity
Alpha GPC greatly enhances my nootropic regimen, particularly in improving short-term memory. I incorporate it with a group of B vitamins, DMAE capsules, and magnesium. Memory issues, even in young individuals, can sometimes stem from forgetfulness due to stress. I encourage anyone facing these challenges, including those concerned about Alzheimer’s, to consider it as it has greatly benefitted me.
Read More
8.8
Supports memory function
Do your research before you take a random supplement you find on Amazon. Not every over-the-counter drug is acceptable to take. That said, this is one of the medications used in Alzheimer's patients. It increases precursors for your body to produce acetylcholine, the neurotransmitter predominantly responsible for muscle function and various other functions, including memory and responsiveness.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 8 Researches
8.1
- All Researches
9
Alpha-GPC reduces Alzheimer's symptoms
Pharmacological enhancement of cholinergic neurotransmission alleviates neuroinflammation and improves functional outcomes in a triple transgenic mouse model of Alzheimer's disease.
High relevance to Alzheimer's treatment
We investigated the potential benefits of alpha-glyceryl-phosphoryl-choline (α-GPC) in tackling the complex challenges of Alzheimer's disease (AD). Using a triple transgenic mouse model known as 3xTg-AD, mice were treated with α-GPC for eight months starting at four months of age. This approach allowed us to assess its impact on both neuroinflammation and memory over a significant timeframe.
Our findings revealed that chronic treatment with α-GPC led to a notable reduction in amyloid deposits, which are often associated with AD. We observed improvements in the balance of the immune response within the brain, especially among important cells like astrocytes and microglia. These changes reflected not just a decrease in inflammation but also an increase in protective, anti-inflammatory molecules.
Furthermore, the treatment positively influenced synaptic function, crucial for memory and learning. Behaviorally, the α-GPC-treated mice demonstrated enhanced cognitive abilities, as evidenced by longer exploration times of new objects—a key indicator of memory function—compared to their untreated counterparts.
In summary, our research supports α-GPC as a promising candidate for therapeutic intervention in the early stages of Alzheimer's. Its ability to reduce inflammation and support brain health could provide new avenues for aiding memory and cognitive function as we age.
Our findings revealed that chronic treatment with α-GPC led to a notable reduction in amyloid deposits, which are often associated with AD. We observed improvements in the balance of the immune response within the brain, especially among important cells like astrocytes and microglia. These changes reflected not just a decrease in inflammation but also an increase in protective, anti-inflammatory molecules.
Furthermore, the treatment positively influenced synaptic function, crucial for memory and learning. Behaviorally, the α-GPC-treated mice demonstrated enhanced cognitive abilities, as evidenced by longer exploration times of new objects—a key indicator of memory function—compared to their untreated counterparts.
In summary, our research supports α-GPC as a promising candidate for therapeutic intervention in the early stages of Alzheimer's. Its ability to reduce inflammation and support brain health could provide new avenues for aiding memory and cognitive function as we age.
Read More
8
α-GPC improves memory in mice
Treatment with soybean lecithin-derived α-GPC (SHCog™) improves scopolamine-induced cognitive declines in mice via regulating cholinergic neurotransmission and enhancing neural plasticity in the hippocampus.
Study relevance is moderately low
We explored how α-GPC, derived from soybean lecithin and known as SHCog™, impacts cognitive decline in mice, particularly looking at memory issues related to scopolamine-induced impairment. The study involved the use of C57BL/6 J mice subjected to tests designed to evaluate their short-term and spatial memory.
Our key findings revealed that treatment with SHCog™ improved both short-term and spatial memory when compared to untreated mice experiencing cognitive decline. Notably, we observed that SHCog™ effectively reduced the levels of acetylcholinesterase (AChE), an enzyme elevated by scopolamine, while increasing choline acetyltransferase (ChAT), which was decreased by the same treatment.
Furthermore, SHCog™ influenced neural plasticity by restoring proteins, such as PSD-95 and brain-derived neurotrophic factor (BDNF), that were reduced due to scopolamine. Overall, our work suggests that incorporating SHCog™ into functional foods or supplements could potentially enhance memory and cognitive functions. However, it’s important to note that these findings, while promising, relate primarily to a mouse model of cognitive dysfunction rather than direct evidence of benefits for Alzheimer's disease in humans.
Our key findings revealed that treatment with SHCog™ improved both short-term and spatial memory when compared to untreated mice experiencing cognitive decline. Notably, we observed that SHCog™ effectively reduced the levels of acetylcholinesterase (AChE), an enzyme elevated by scopolamine, while increasing choline acetyltransferase (ChAT), which was decreased by the same treatment.
Furthermore, SHCog™ influenced neural plasticity by restoring proteins, such as PSD-95 and brain-derived neurotrophic factor (BDNF), that were reduced due to scopolamine. Overall, our work suggests that incorporating SHCog™ into functional foods or supplements could potentially enhance memory and cognitive functions. However, it’s important to note that these findings, while promising, relate primarily to a mouse model of cognitive dysfunction rather than direct evidence of benefits for Alzheimer's disease in humans.
Read More
8
Alpha GPC's effect on AD inflammation
Taming Microglia in Alzheimer's Disease: Exploring Potential Implications of Choline Alphoscerate via α7 nAChR Modulation.
Moderate relevance to Alzheimer's research
We investigated how choline alphoscerate (α-GPC), a compound that enhances cholinergic neurotransmission, could influence microglial cells in the context of Alzheimer's disease (AD). Recognizing that AD often leads to cognitive challenges due to cholinergic dysfunction, we turned our attention to the potential therapeutic benefits of α-GPC.
In our study, we analyzed the effects of α-GPC on BV2 microglial cells, a model for understanding microglial behavior. By pre-treating these cells with α-GPC and exposing them to amyloid-beta (Aβ) proteins, we aimed to see if α-GPC could counteract the inflammatory responses typically induced by Aβ.
Our findings indicated that α-GPC effectively alleviated Aβ-induced inflammation by activating the alpha-7 nicotinic acetylcholine receptor (α7 nAChR). This activation spurred an increase in calcium levels and related neuronal signals, suggesting a direct mechanism of action.
Overall, we discovered that modulating cholinergic transmission through α-GPC might hold promise as a strategy for improving outcomes in neurodegenerative conditions like Alzheimer's, as it seems to impact the inflammatory profiles of glial cells positively.
In our study, we analyzed the effects of α-GPC on BV2 microglial cells, a model for understanding microglial behavior. By pre-treating these cells with α-GPC and exposing them to amyloid-beta (Aβ) proteins, we aimed to see if α-GPC could counteract the inflammatory responses typically induced by Aβ.
Our findings indicated that α-GPC effectively alleviated Aβ-induced inflammation by activating the alpha-7 nicotinic acetylcholine receptor (α7 nAChR). This activation spurred an increase in calcium levels and related neuronal signals, suggesting a direct mechanism of action.
Overall, we discovered that modulating cholinergic transmission through α-GPC might hold promise as a strategy for improving outcomes in neurodegenerative conditions like Alzheimer's, as it seems to impact the inflammatory profiles of glial cells positively.
Read More
8
Alpha GPC shows cognitive benefits
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.
Effectiveness partly unclear due to combinations
We explored the effectiveness of alpha glyceryl phosphorylcholine, commonly known as alpha GPC, in improving cognitive function for individuals with Alzheimer's and other adult-onset neurological disorders. To gain insight, we reviewed relevant studies by sifting through databases like PubMed, Web of Science, and Embase.
Our analysis led us to include findings from seven randomized controlled trials and one prospective cohort study, focusing specifically on how alpha GPC, both alone and alongside donepezil, affects cognition, functionality, and behavior in patients. The results revealed that using alpha GPC, especially in conjunction with donepezil, showed significant promise. This combination appears to enhance cognition, improve functional outcomes, and potentially lead to better behavioral results.
We observed that patients taking alpha GPC demonstrated better cognitive abilities compared to those receiving either placebo or other treatments. This finding might offer hope for individuals struggling with cognitive functions related to Alzheimer’s. However, it’s important to note that while alpha GPC shows benefits, clarity around its independent effectiveness remains, given its frequent combination with donepezil in trials.
Overall, our findings suggest that alpha GPC could be beneficial for cognitive enhancement in Alzheimer’s, especially in combination therapies. But further investigation is warranted to fully understand its standalone potential.
Our analysis led us to include findings from seven randomized controlled trials and one prospective cohort study, focusing specifically on how alpha GPC, both alone and alongside donepezil, affects cognition, functionality, and behavior in patients. The results revealed that using alpha GPC, especially in conjunction with donepezil, showed significant promise. This combination appears to enhance cognition, improve functional outcomes, and potentially lead to better behavioral results.
We observed that patients taking alpha GPC demonstrated better cognitive abilities compared to those receiving either placebo or other treatments. This finding might offer hope for individuals struggling with cognitive functions related to Alzheimer’s. However, it’s important to note that while alpha GPC shows benefits, clarity around its independent effectiveness remains, given its frequent combination with donepezil in trials.
Overall, our findings suggest that alpha GPC could be beneficial for cognitive enhancement in Alzheimer’s, especially in combination therapies. But further investigation is warranted to fully understand its standalone potential.
Read More
8
Alpha GPC shows cognitive benefits
[Clinical and immunological effects of choline alfoscerate in the treatment of amnestic type Mild Cognitive Impairment].
Relevant to Alzheimer's treatment research.
We explored the impact of Choline alfoscerate, commonly known as Alpha GPC, on patients suffering from amnestic Mild Cognitive Impairment (aMCI), a condition linked to an increased risk of developing Alzheimer's disease. Over the course of three months, thirty patients aged 56 to 82 took Alpha GPC in a dosage of 1200 mg per day to assess its therapeutic effects.
The results showed promising improvements in cognitive abilities, evaluated through psychometric tests like the Mini-Mental State Examination (MMSE) and the Boston Naming Test. Additionally, we observed changes in certain immunological markers, specifically leukocyte elastase levels. These findings suggest that patients displayed better cognitive function alongside increased levels of this particular immune marker after treatment with Alpha GPC.
Importantly, our study highlights a potential relationship between cognitive improvements and the immune response triggered by Alpha GPC. While these results are encouraging, the need for further research is clear, particularly to understand the immune mechanisms at play. Such insights could help us develop better predictive markers for the treatment effects of Alpha GPC on individuals at risk for Alzheimer's disease.
The results showed promising improvements in cognitive abilities, evaluated through psychometric tests like the Mini-Mental State Examination (MMSE) and the Boston Naming Test. Additionally, we observed changes in certain immunological markers, specifically leukocyte elastase levels. These findings suggest that patients displayed better cognitive function alongside increased levels of this particular immune marker after treatment with Alpha GPC.
Importantly, our study highlights a potential relationship between cognitive improvements and the immune response triggered by Alpha GPC. While these results are encouraging, the need for further research is clear, particularly to understand the immune mechanisms at play. Such insights could help us develop better predictive markers for the treatment effects of Alpha GPC on individuals at risk for Alzheimer's disease.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.6
- All Reviews
- Positive Reviews
- Negative Reviews
8.8
Enhances memory clarity
Alpha GPC greatly enhances my nootropic regimen, particularly in improving short-term memory. I incorporate it with a group of B vitamins, DMAE capsules, and magnesium. Memory issues, even in young individuals, can sometimes stem from forgetfulness due to stress. I encourage anyone facing these challenges, including those concerned about Alzheimer’s, to consider it as it has greatly benefitted me.
Read More
8.8
Supports memory function
Do your research before you take a random supplement you find on Amazon. Not every over-the-counter drug is acceptable to take. That said, this is one of the medications used in Alzheimer's patients. It increases precursors for your body to produce acetylcholine, the neurotransmitter predominantly responsible for muscle function and various other functions, including memory and responsiveness.
Read More
